Related Experiment Video
Updated: Nov 29, 2025

Studying Pancreatic Cancer Stem Cell Characteristics for Developing New Treatment Strategies
Published on: June 20, 2015
Molecular Features of Cancers Exhibiting Exceptional Responses to Treatment
David A Wheeler1, Naoko Takebe2, Toshinori Hinoue3
1Human Genome Sequencing Center, Baylor College of Medicine, Houston, TX 77030, USA; Dan L. Duncan Cancer Center, Baylor College of Medicine, Houston, TX 77030, USA.
Abstract:
A small fraction of cancer patients with advanced disease survive significantly longer than patients with clinically comparable tumors. Molecular mechanisms for exceptional responses to therapy have been identified by genomic analysis of tumor biopsies from individual patients. Here, we analyzed tumor biopsies from an unbiased cohort of 111 exceptional responder patients using multiple platforms to profile genetic and epigenetic aberrations as well as the tumor microenvironment. Integrative analysis uncovered plausible mechanisms for the therapeutic response in nearly a quarter of the patients. The mechanisms were assigned to four broad categories-DNA damage response, intracellular signaling, immune engagement, and genetic alterations characteristic of favorable prognosis-with many tumors falling into multiple categories. These analyses revealed synthetic lethal relationships that may be exploited therapeutically and rare genetic lesions that favor therapeutic success, while also providing a wealth of testable hypotheses regarding oncogenic mechanisms that may influence the response to cancer therapy.
Insights
Molecular mechanisms behind exceptional cancer responses were uncovered in advanced disease patients. Analyzing tumor genetics and microenvironments revealed key pathways like DNA damage response and immune engagement.
Area of Science:
- Oncology
- Genomics
- Cancer Biology
Background:
- A small subset of advanced cancer patients exhibit prolonged survival despite similar clinical prognoses.
- Understanding the molecular basis of these exceptional responses is crucial for advancing cancer therapy.
Purpose of the Study:
- To investigate the genetic, epigenetic, and microenvironmental factors contributing to exceptional responses in cancer patients.
- To identify actionable therapeutic targets and hypotheses for overcoming treatment resistance.
Main Methods:
- Comprehensive genomic and epigenomic profiling of tumor biopsies from 111 exceptional responders.
- Analysis of the tumor microenvironment using multiple high-throughput platforms.
- Integrative analysis of multi-platform data to uncover response mechanisms.
Main Results:
- Plausible therapeutic response mechanisms were identified in nearly 25% of exceptional responders.
- Mechanisms were categorized into DNA damage response, intracellular signaling, immune engagement, and favorable genetic alterations.
- Many tumors exhibited mechanisms across multiple categories, highlighting complex interactions.
Conclusions:
- Integrative analysis of exceptional responders reveals diverse molecular mechanisms underlying prolonged survival.
- Identified synthetic lethal relationships and rare genetic lesions offer potential therapeutic strategies.
- The study provides a foundation for further research into oncogenic mechanisms and treatment response.
Related Concept Videos
Treatment Resistant Cancers
Targeted Cancer Therapies
There are several types of targeted therapies against...
Adaptive Mechanisms in Cancer Cells
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Cancer Stem Cells and Tumor Maintenance
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Cancer

